Table 1.
Patient characteristics for the whole study population
| SABR | CFRT | Standardized difference (rounded)* | |||||
|---|---|---|---|---|---|---|---|
| Number or mean (sd)* | (%)* | Number or mean (sd)* | (%)* | Before IPW | After | ||
| Age | 77.81 (7.85) | 75.40 (9.96) | 0.27 | 0.24 | |||
| Sex | Female | 20 | (29) | 44 | (26) | 0.07 | 0.07 |
| Male | 49 | (71) | 125 | (74) | |||
| Residency | Non-north | 32 | (46) | 93 | (55) | 0.17 | 0.19 |
| North | 37 | (54) | 76 | (45) | |||
| Comorbidity | Without | 9 | (13) | 43 | (25) | 0.32 | 0.25 |
| With† | 60 | (87) | 126 | (75) | |||
| Histology | Adenocarcinoma | 40 | (58) | 82 | (49) | 0.19 | 0.24 |
| Non-adenocarcinoma | 29 | (42) | 87 | (51) | |||
| T stage | T1 | 38 | (55) | 49 | (29) | 0.55 | 0.08 |
| T2 | 31 | (45) | 120 | (71) | |||
| Period | 2007–2009 | 15 | (22) | 65 | (38) | 0.37 | 0.22 |
| 2010–2013 | 54 | (78) | 104 | (62) | |||
| Use of PET | Yes | 37 | (54) | 55 | (33) | 0.44 | 0.09 |
| No | 32 | (46) | 114 | (67) | |||
| Use of systemic therapy | Yes | 10 | (14) | 73 | (43) | 0.67 | 0.17 |
| No | 59 | (86) | 96 | (57) | |||
| Previous cancer | Yes | 9 | (13) | 16 | (9) | 0.11 | 0.06 |
| No | 60 | (87) | 153 | (91) | |||
CFRT = conventional fractionated radiotherapy; IPW = inverse probability weighting; PET = positron emission tomography; SABR = stereotactic ablative radiotherapy; sd = standard deviation;
*
rounded at the second
†
modified Carlson comorbidity score ≥ 1